Health
Rutgers leading coronavirus therapeutic clinical trial – EurekAlert
Rutgers is leading a clinical trial assessing the combination of nitazoxanide, ribavirin and hydroxychloroquine to treat people 21 or older who are infected with…
Rutgers is leading a clinical trial assessing the combination of nitazoxanide, ribavirin and hydroxychloroquine to treat people 21 or older who are infected with SARS-CoV-2 and are asymptomatic or mildly symptomatic. The trial is being conducted with Synavir Corporation, a global health company that works with academia, industry and government to develop combination treatments for new viral infections.
The trial — called Triple Combination Antiviral Coronavirus Therapy (TriACT) — seeks to determine…
-
Business20 hours agoWhy Vault Minerals, Droneshield, Westgold Resources shares are climbing higher today
-
Noosa News15 hours agoRacing Queensland responds to criticism of ‘deadliest’ greyhound track
-
Noosa News23 hours agoDramatic details emerge of moment woman loses arm in attack by lion in Queensland Zoo
-
General19 hours agoTrump’s AUKUS review coming soon. Will he stop the folly?